AstraZeneca attractive in near term but patent cliffs loom, says broker
AstraZeneca's project pipelines means it has positive near-term prospects, but Jefferies lowered earnings forecasts
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 15 of 55
AstraZeneca a ‘buy’ for project pipeline potential – broker
Shore reiterated a price target of £127 by the end of 2023, up from almost £114 currently.
AstraZeneca a buy after strong quarter- Shorecap
Shore Capital Group Ltd reiterated its recommendation that AstraZeneca was a buy after strong quarterly results
AstraZeneca raises earnings guidance as profit margins improve
Last year's acquisition of Alexion and a "favourable product mix" had a positive impact
AstraZeneca receives backing for new rescue inhaler
The new product is being developed jointly by AZ and UK group Avillion
AstraZeneca says Beyfortus gets EU approval for respiratory virus in infants
Beyfortus is the first and only single-dose respiratory syncytial virus (RSV) passive immunisation for the broad infant population
AstraZeneca shares will get lift from heartburn drug litigation closure, says Citi
The UK pharma is one of several firms embroiled in US legal action over possible kidney damage
AstraZeneca trial of Fasrena fails to help with eosinophilic esophagitis swallowing problems
Eosinophilic esophagitis is a rare, progressive, chronic inflammatory disease of the oesophagus, which can lead to difficulty with swallowing, pain, food getting stuck and anxiety
AstraZeneca says Imjudo-Imfinzi combination approved for advanced liver cancer in US
The HIMALAYA Phase III trial showed that a single priming dose of Imjudo added to Imfinzi reduced the risk of death by 22% compared with sorafenib
AstraZeneca earnings to fall due to lower sales and higher costs
AstraZeneca core average earnings per share will fall 5.5% predicts Credit Suisse
AstraZeneca set for strong third-quarter; brokers think the stock is worth £125
Shore Capital is one of 21 banks and brokers following AZ that are bullish on the outlook for the Anglo-Swedish drugs giant and its share price
AstraZeneca sees COVID-19 vaccine suffer a setback in nasal spray trial
An antibody response in the respiratory mucous membranes was seen in only a minority of participants in the trial, which was in the first of usually three phases of clinical testing, the University of Oxford said in a statement
AstraZeneca gets its third regulatory green light in a matter of weeks for asthma drug
The treatment has been approved in Japan for severe bronchial asthma where high-dose traditional corticosteroids don’t work
AstraZeneca wins European approval for Ultomiris autoimmune disease treatment
The nod from the European Commission paves the way for the first long-acting C5 inhibitor for generalised myasthenia gravis
AstraZeneca receives China green light for Lynparza
The drug will be used as a maintenance treatment in women with an advanced form of ovarian cancer
AstraZeneca says Evusheld approved for treatment of COVID-19 in EU
Evusheld has been shown to significantly reduce the risk of severe COVID-19 or death
AstraZeneca gets EU backing for COVID-19 treatment and RSV drug
If Beyfortus receives marketing approval, it would be the first single-dose preventative therapy for RSV for infants
Archive
Market movers: Property groups fall as Goldman/JPMorgan reduce price targets
A look at some risers and fallers in the market today.